67 articles
This post presents a statistical overview of pharmaceutical patents in India over the past decade, focusing on trends and key contributors. It objectively discusses the impact of legal…
The Indian Patent Office has revoked Roche’s Valganciclovir patent, emphasizing Section 3d and public interest. This decision strengthens access to medicines in India and curbs evergreening by pharmaceutical…
The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim…
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C…
The Indian Patent Office has revoked Roche’s patent on Bonviva after Cipla challenged its validity, citing a lack of inventive step and patentability. This decision highlights critical aspects…
This post critically examines whether Section 3d serves as an extension of the inventive step analysis or as a separate requirement under Indian patent law. It discusses the…
The Novartis case established a strict test for therapeutic efficacy under Section 3(d) of the Indian Patents Act, influencing the patentability of genetic inventions. This post examines the…